
It took some time, but Novo Nordisk may be facing the first real test of its dominance in the weight loss market after pharmaceutical giant Eli Lilly won approval for its own Wegovy rival.
U.S. regulators signed off on Eli Lilly’s diabetes drug Zepbound, which can also be used to aid weight loss. The drug was found to help patients lose 18% of their body weight in control trials.